Stock Events

Stock Events

Mainz Biomed N.V. 

$0.84
110
+$0.02+2.07% Wednesday 20:00

Statistics

Day High
0.86
Day Low
0.74
52W High
5.34
52W Low
0.55
Volume
5,235,144
Avg. Volume
625,473
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14AprExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-5.2
-3.52
-1.83
-0.15
Expected EPS
-1.01
Actual EPS
N/A

Financials

-2,424.52%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.79MRevenue
-43.3MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MYNZ. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Exact Sciences
EXAS
Mkt Cap20.03B
Exact Sciences Corp. offers Cologuard, a non-invasive stool DNA screening test for colorectal cancer, directly competing with Mainz Biomed's colorectal cancer detection technologies.
Guardant Health
GH
Mkt Cap12.31B
Guardant Health, Inc. provides liquid biopsy tests that detect cancer and cancer treatment targets, competing in the broader cancer diagnostics market.
Fulgent Genetics
FLGT
Mkt Cap525.3M
Fulgent Genetics, Inc. provides comprehensive genetic testing solutions for various diseases, including cancer, competing in the genetic testing market.
Qiagen NV
QGEN
Mkt Cap8.46B
Qiagen N.V. offers sample and assay technologies for molecular diagnostics, including cancer, competing in the molecular diagnostics market.
Pacific Biosciences of California
PACB
Mkt Cap404.68M
Pacific Biosciences of California, Inc. offers sequencing systems that could be used in cancer research and diagnostics, indirectly competing in the genomics space.
Illumina
ILMN
Mkt Cap19.48B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, which are crucial in cancer research and diagnostics, making it a competitor in the genomics field.
TG Therapeutics
TGTX
Mkt Cap5.35B
TG Therapeutics, Inc. focuses on developing treatments for B-cell malignancies and autoimmune diseases, competing in the broader oncology and biopharmaceutical market.
Adaptive Biotechnologies
ADPT
Mkt Cap2.28B
Adaptive Biotechnologies Corp. offers clonoSEQ, a diagnostic test for detecting minimal residual disease in blood cancers, competing in the cancer diagnostics and monitoring market.

About

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Show more...
CEO
Mr. Guido Baechler
Employees
19
Country
US
ISIN
NL0015000LC2

Listings

XNAS
US
MYNZ
F
DE
4TO.F
BOATS
BOATS
MYNZ.BOATS
XNAS
US
QUCY

0 Comments

Share your thoughts

FAQ

What is Mainz Biomed N.V. stock price today?▼
The current price of MYNZ is $0.84 USD — it has increased by +2.07% in the past 24 hours. Watch Mainz Biomed N.V. stock price performance more closely on the chart.
What is Mainz Biomed N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Mainz Biomed N.V. stocks are traded under the ticker MYNZ.
Is Mainz Biomed N.V. stock price growing?▼
MYNZ stock has risen by +0% compared to the previous week, the month change is a +1.7% rise, over the last year Mainz Biomed N.V. has showed a -72.42% decrease.
When is the next Mainz Biomed N.V. earnings date?▼
Mainz Biomed N.V. is going to release the next earnings report on April 14, 2026.
What is Mainz Biomed N.V. revenue for the last year?▼
Mainz Biomed N.V. revenue for the last year amounts to 1.79M USD.
What is Mainz Biomed N.V. net income for the last year?▼
MYNZ net income for the last year is -43.3M USD.
How many employees does Mainz Biomed N.V. have?▼
As of April 08, 2026, the company has 19 employees.
In which sector is Mainz Biomed N.V. located?▼
Mainz Biomed N.V. operates in the Health Care sector.
When did Mainz Biomed N.V. complete a stock split?▼
The last stock split for Mainz Biomed N.V. was on December 03, 2024 with a ratio of 1:40.
Where is Mainz Biomed N.V. headquartered?▼
Mainz Biomed N.V. is headquartered in Mainz, US.